Surf Bio Announces $1.6 Million Non-Dilutive Grant

Surf Bio, Inc., a biopharmaceutical company commercializing a novel drug stabilization platform, has received a $1.6 million grant from the Bill & Melinda Gates Foundation. The grant will provide funding to evaluate the use of the company's lead technology toward increasing the thermostability and deliverability of a monoclonal antibody in low- and middle-income countries.

Surf Bio's novel polymer technology enables the formulation of biologics at higher concentrations and in a more thermostable form than is currently available. Surf Bio's technology offers significant opportunities for improving the accessibility of advanced therapeutics in low- and middle-income countries by eliminating the requirement for refrigeration and enabling subcutaneous administration of biologics.

"Surf Bio's stabilization platform enables pharmaceutical formulations and delivery in resource-constrained settings that are not currently possible with today's technologies," said Bryan Mazlish, co-founder and CEO, Surf Bio. "We are thrilled to receive support from the Bill & Melinda Gates Foundation to advance the use of our technology to enable greater access to biologics in low- and middle-income countries."

Surf Bio has ongoing collaborations with leading multinational pharmaceutical companies exploring the use of the polymer technology within their proprietary product pipelines. To date, in-vitro and in-vivo safety and efficacy data has demonstrated that Surf Bio's platform may enable drug developers to produce temperature stable formulations, very high concentration subcutaneous formulations, and novel therapeutics formulations that would not otherwise be possible.

About Surf Bio

Surf Bio is a preclinical biopharmaceutical company that is leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for oncology, autoimmune diseases, infectious diseases, gene therapy, and other therapeutic areas. Surf Bio was launched by the founders of Bigfoot Biomedical and Mode AGC to commercialize a breakthrough drug stabilization technology developed in the Appel lab at Stanford University. Commercially, the technology is designed to enable reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas. For more information about Surf Bio, visit www.surf.bio.